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Background 38 
In postmarketing vaccine surveillance, adverse events observed in a vaccinated population are 39 
compared to the number expected based on a background incidence rate. The background rate should 40 
be accurate and obtained from a population comparable to the one vaccinated. Such rates are often 41 
not available. 42 
Methods 43 
The incidence rate of generalised convulsive, febrile and afebrile seizures was estimated in individuals 44 
born after 01-January-1998 and aged between 2 months and 15 years of age using the UK Clinical 45 
Practice Research Datalink (1999-2011). 46 
Results 47 
The study population consisted of 1,532,992 individuals (4,917,369 person years (PY) of follow up). A 48 
total of 28,917 generalised convulsive seizure events were identified during follow-up, the overall 49 
incidence rate was 5.88 per 1,000PY. Age specific rates increased sharply from 4/1,000PY at 2 months 50 
of age, peaked at 19/1,000PY at 16 months and decreased until approximately 6 years of age at which 51 
point they became relatively stable at 2/1,000PY. 67% of GCSs were categorised as febrile: 56% using 52 
Read codes, 11% using free text. Febrile seizures accounted for the age trend in GCS, with rates 53 
peaking at 16.1/1,000PY at 16 months of age while afebrile seizure rates remained relatively stable 54 
across all ages (24 seizures per 1,000PY). Analysis by first occurrence of febrile seizure showed a similar 55 
pattern, comparable to published studies on the incidence of seizures in childhood. 56 
Discussion 57 
The rates reported in this study could be used in the postmarketing surveillance of infant vaccines. 58 
However, given the variation across strata, and the potential underascertainment of seizure events 59 
presenting to A&E, care must be taken when interpreting and using these rates.  60 
Background 61 
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Generalised convulsive seizures (GCS) are episodes of neuronal hyperactivity resulting in involuntary 62 
muscle contraction and impairment or loss of consciousness. [1]. GCS can result from known causes 63 
such as epilepsy syndromes, central nervous system infections and acute electrolyte imbalances, 64 
however most remain idiopathic [2]. 65 
Febrile seizures (FS) are a particular type of idiopathic GCS in which seizure onset is preceded by a 66 
fever [3]. They are the most common type of seizure with up to 5% of the population suffering at least 67 
one FS before 5 years of age [4-6]. The incidence of febrile seizures is highest between 6 and 36 months 68 
of age and has been shown to peak at approximately 18 months of age [7]. Approximately one third 69 
of individuals who have a febrile seizure will suffer a recurrence, with family history, lower peak 70 
temperature of fever, short duration of fever and febrile seizures in young individuals being associated 71 
with a greater risk of recurrence [8, 9]. 72 
A number of vaccines have been linked with an increased risk of febrile seizure, most notably the 73 
measles, mumps and rubella (MMR) vaccine [10], the whole cell pertussis (DTP) vaccine [11] and the 74 
CSL pandemic (H1N1) influenza vaccine [12]. As a result, (febrile) seizures are commonly prioritised 75 
for close surveillance in vaccine safety monitoring. 76 
Prior to the 2009 pandemic vaccination campaign Black et al highlighted the importance of 77 
background incidence rates, in vaccine surveillance [13]. They illustrated how such rates can be used 78 
as an expected rate against which the rates observed in a vaccinated population could be compared. 79 
They also underlined the need to be aware of any geographic, ethnic and age differences in such rates 80 
and their dependence on the method used to develop the rates. Examples of their use during the 2009 81 
pandemic can be found in the literature [14, 15]. Background incidence rates of GCS for the United 82 
Kingdom are not widely available in the published literature [4, 16] and they lack the appropriate level 83 
of stratification for use in an infant vaccine programme. This study seeks to investigate the incidence 84 
of GCS in infants, children and adolescents in the UK Clinical Practice Research Datalink (CPRD) and to 85 
determine whether the CPRD can accurately categorise GCS by distinguishing FS from afebrile GCS. 86 
 4 
 
Methods 87 
This study was carried out using the UK Clinical Practice Research Datalink (CPRD). The CPRD is an 88 
electronic healthcare database containing the anonymised primary care medical records of ~8.4% of 89 
the UK general population. Patient data routinely collected in primary care and therefore available in 90 
the database include demographic details, diagnoses and symptoms including those leading to 91 
hospital admissions, immunisations, pregnancies, laboratory tests, referrals to specialists, 92 
prescriptions issued by the general practitioner (GP, primary care physician) and deaths [17, 18]. In 93 
the UK a patient’s primary care record is considered their main electronic health record therefore 94 
events occurring in secondary care (e.g. emergency room visits, hospital inpatient events) should be 95 
reported to a patient’s GP and entered into their record. Despite this, recording of secondary care 96 
data in the primary care record is incomplete. Clinical events in the CPRD are recorded using clinical 97 
codes known as a Read codes. There are currently over 100,000 Read codes each of which is associated 98 
with a short description of varying specificity. Diagnostic Read codes can be considered equivalent to 99 
ICD codes, with many mapping directly to specific ICD codes, however a range of additional Read codes 100 
exist to facilitate the complexities of patient management in primary care. In order to further facilitate 101 
the management of patients in primary care, recording of additional, unstructured textual information 102 
in association with a Read code is also possible. This information, commonly referred to as ‘free text’, 103 
generally contains elaborations on the information in the coded record.  104 
The study period ran from 01-January-1999 to the 31-December-2011. The study population 105 
comprised individuals permanently registered in the CPRD and aged between 2 and 180 months (15 106 
years) at some point during the study period. Follow up of each patient began at the start of the study 107 
period, an age of 2 months or the date of registration with the CPRD, whichever was latest. Follow up 108 
ended at the end of the study period, an age of 180 months, date of death or transfer out of the GP 109 
practice, whichever is earliest.  110 
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In the CPRD the month of birth is only available for individuals aged less than 15 years old.  Individuals 111 
born before the 01-January-1998 had reached the age of 15 before the end of the study period and 112 
therefore did not have a record of their month of birth available. Individuals were therefore excluded 113 
from the study population if they were born before 01-January-1998. 114 
Our definition of GCS generally followed the Brighton Collaboration definition [1] in that it sought to 115 
include all convulsive seizures regardless of their cause and nature. Primary care data, such as that 116 
contained in the CPRD, is often unsuited to classification of cases at specific Brighton collaboration 117 
classification levels as data on many of the necessary classification criteria are not commonly recorded 118 
in general practice. As a result we did not attempt to define cases at specific Brighton collaboration 119 
classification levels. Operationally, GCS events were therefore identified as any event recorded against 120 
one of the seizure related Read codes listed in tables A1.1, A1.2 or A1.3 in supplementary file 1. 121 
We sought to separate GCS events into those that were febrile and afebrile. Two clinical definitions of 122 
febrile seizure can be found in the published literature [3, 19]. Both of these define a febrile seizure 123 
as a seizure which is associated with a fever and occurs in an individual aged less than 5 years old with 124 
no central nervous system infections and with no history of afebrile seizure. The primary difference 125 
between these two definitions is the minimum age at which they determine a seizure can be defined 126 
as febrile (1 vs. 3 months). Taking both the nature of CPRD data and these clinical definitions of febrile 127 
seizures into account, in this study a febrile seizure was defined as any seizure occurring in association 128 
with a fever in an individual: aged greater than 1 month old, with no evidence of central nervous 129 
system infection and with no history of epilepsy. Note that the exclusion of all individuals with a 130 
history of afebrile seizure was not included in this definition as the sensitivity of such an exclusion 131 
criterion in the CPRD is likely to be poor. Operationally, febrile seizures meeting this definition were 132 
identified in the CPRD using (a) a code for febrile seizure, (b) a code for seizure and a code for fever or 133 
febrile seizure recorded within 2 weeks either side (c) a code for seizure and a free text entry indicating 134 
a fever was present. In line with our clinical definition of febrile seizure, events identified under 135 
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definitions (a), (b) and (c) were not considered febrile if central nervous system infections were 136 
recorded in the patient’s record in the 2 weeks before or 6 weeks after the event or if an epilepsy code 137 
was recorded anywhere prior to the event. The codes defining such events are provided in Table A1.5 138 
and Table A1.6 of supplementary file 1. 139 
All GCS events that did not meet the above definition of a febrile seizure were considered afebrile 140 
seizure events. 141 
The total number of GCS events in age, sex and calendar year specific periods were calculated and 142 
used as the numerators in the stratified incidence rates. The amount of person-time contributed by 143 
the study population in each age, sex and calendar year specific period was calculated and used as the 144 
denominator in the stratified incidence rates. Unless otherwise specified, all incidence rates were 145 
reported as numbers of seizures per 1,000 person years (PY). Confidence intervals were estimated 146 
assuming a normal binomial distribution for all rates. As per CPRD policy, strata with <5 events are 147 
reported as <5 and no incidence rates were calculated. Rates of afebrile and febrile seizures were 148 
calculated using the same method. In addition, rates of first GCS, febrile and afebrile seizure were 149 
estimated by including only the first event per individual in the numerator and censoring follow up for 150 
the denominator at first seizure occurrence. The total number of events and the number of first events 151 
that could be expected in given time periods after vaccination of a hypothetical cohort of children was 152 
also calculated by multiplying the incidence rates by the parameters describing the hypothetical 153 
population. 154 
 155 
Results 156 
The study population consisted of 1,173,916 individuals who contributed 4,917,369 person years of 157 
follow up during the study period. A total of 28,917 GCS events were identified during follow-up 158 
providing an overall incidence rate of GCS in the entire study population of 5.88 per 1,000 PY. Figure 159 
1 and Table 1 show age specific incidence rates of GCS. Rates increased sharply from 3.5/1,000 PY at 160 
 7 
 
2 months of age, peaked at 19.2/1,000 PY at 16 months and decreased until approximately 6 years of 161 
age at which point they became relatively stable at approximately 2/1,000 PY.  The incidence rate for 162 
those aged between 2 months and 5 years was 8.99 per 1,000 PY. 163 
No meaningful differences were observed between the sex specific rates of GCS (data not shown). 164 
Table A2.1 (Supplementary file 2) shows the age category specific incidence of GCS across calendar 165 
years. The distribution by age was similar within calendar years. However, rates decreased slightly 166 
over time. 167 
There were 19,622 febrile seizure events and 9,295 afebrile seizure events resulting in overall 168 
incidence rates of 4.01 and 1.89 seizures per 1,000 PY respectively. Figure 1 and Table 1 compare age 169 
specific incidence rates of febrile, afebrile and generalised convulsive seizure. The rate of afebrile 170 
seizure remained stable across ages (2-4 seizures per 1,000 person years). In contrast, febrile seizure 171 
rates account for the peak in the GCS incidence rate at 18 months and the general trend observed up 172 
to 6 years. After 5 years of age the rate of febrile seizures is lower than that of afebrile. The incidence 173 
rate for those aged between 2 months and 5 years was 6.68 per 1,000 PY for febrile seizure and 2.32 174 
per 1,000 PY for afebrile seizure. No meaningful sex distribution was observed for febrile/afebrile 175 
seizure (data not shown). Table 3 describes the proportion of febrile seizures that were identified 176 
using each of the three case identification methods. 177 
When the analysis was restricted to first events 18,336 GCS events were identified during 4,837,363 178 
person years of follow up, 14,015 febrile seizure events were identified during 4,839,251 person years 179 
of follow up and 5,447 afebrile seizure events were identified during 4,895,611 person years of follow 180 
up.  This resulted in overall incidence rates of 3.79, 2.90 and 1.11 seizures per 1,000 PY respectively. 181 
Figure 2 and Table 2 show age specific incidence rates of first febrile, afebrile and generalised 182 
convulsive seizure. While the age specific rates of first seizure are unsurprisingly lower than those for 183 
all seizures, the distribution across age categories is similar to that for all seizures.  Gender and year 184 
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specific rates of first seizure showed similar distributions to rates for all events (Table A2.2, 185 
supplementary file 2). 186 
Supplementary file 3 contains interactive tables which can be used to obtain the incidence rates and 187 
expected numbers of first/all febrile, afebrile or generalised convulsive seizure events for reader-188 
defined age, sex and calendar year stratum, in addition the reader can alter the number of individuals 189 
vaccinated and the duration of surveillance. 190 
 191 
Discussion 192 
This study reports month of age specific incidence rates of generalised convulsive, febrile and afebrile 193 
seizures for children and adolescents in the CPRD, the incidence rates can be used to calculate the 194 
expected numbers of seizures in an infant childhood vaccination programme.  195 
The analysis by first occurrence of GCS was included to compare the results for the categorisation of 196 
febrile and afebrile seizures with the literature [5, 20]. The pattern is similar with FS less common than 197 
afebrile seizures in the first few months of life , increasing thereafter to reach a peak in the second 198 
year of life, then dropping sharply from the third year of life to become less frequent than afebrile 199 
seizures after four or five years of age.  The results suggest the CPRD can reliably identify FS. Our use 200 
of diagnostic codes associated with fever identified 4% of FS, while our use of free text strings 201 
associated with fever identified 16% of FS (Table 3). While we have not validated the febrile nature of 202 
seizures identified using each of the methods we believe that similar approaches should be considered 203 
when seeking to distinguish febrile seizures from afebrile seizures on the CPRD. If specificity were 204 
preferable, the case definition used could be amended to include only a record of fever within seven 205 
days of the record of seizure. 206 
The CPRD provides a large, well-defined source population which has been shown to be representative 207 
of the age and sex distribution of the UK population [21, 22]. A disadvantage of the CPRD is that 208 
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seizures may not always be recorded in a patients’ general practice record using a relevant Read code 209 
when patients with seizures present directly to Accident and Emergency (A&E) services (secondary 210 
care). Comparing  CPRD incidence rates to  those reported in the literature (Table 4) the incidence 211 
rates we observed in the CPRD are between 10% and 88% lower than those observed in  prospective 212 
follow-up studies [20, 23, 24] and electronic heath record studies in the Danish National Hospital 213 
Register [11, 16] that all included A&E data. The exception is a third Danish study, which also used the 214 
Danish National Hospital Register (but only included primary discharge diagnoses) [25]. This illustrates 215 
the importance of understanding the methods used to produce the rates .The impact of A&E events 216 
is most evident in the VAESCO [16] data that used standardized methodology across several European 217 
electronic health record databases and shows a markedly higher incidence in the Danish data source 218 
that included A&E data.  219 
In future, ascertainment of seizure events on the CPRD might be improved through linkage with 220 
Hospital Episode Statistics (HES) data; however the quality of HES A&E data remains questionable [26]. 221 
In the absence of such linkage, an alternative option to increase the ascertainment of seizures 222 
presenting in secondary care would be to search the free text associated with Read codes such as 223 
“discharge summary”, “hospital discharge letter” or “Seen in A&E” for key words related to a seizure. 224 
This would allow for the identification of events in which the general practice has been informed of 225 
event occurrence but has recorded the event in the free text associated with a non-seizure diagnostic 226 
code rather than using a seizure specific code.  227 
False positive outcome misclassification may also have occurred in this study, for example if diagnostic 228 
codes for seizure had been used to record follow up consultations about an earlier recorded seizure 229 
episode. While we have not formally investigated the extent of positive or negative misclassification, 230 
overall, we expect the magnitude of false negative misclassification to outweigh any false positive 231 
misclassification and therefore suggest that our rates be assumed to under-estimate the true rate of 232 
seizures in the population. Additionally, the event dates used in this study may reflect the date an 233 
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event was recorded in the database rather than the date of event occurrence; this may have a small 234 
impact on our age and calendar year specific rates. 235 
In observed vs expected calculations the number of subjects exposed to the vaccine is often the least 236 
accurate of the inputs, and similarly the results are generally more sensitive to the risk window 237 
selected than to variations in the background rate. Nevertheless it is important to select the most 238 
accurate background rate available. If the required age strata are available from a data source in a 239 
different geographic region which includes A&E events then using these as inputs would be preferable 240 
to using a geographically accurate source which lacks A&E events as Table 3 shows less variation due 241 
to geography (within Europe) than to inclusion of A&E events.  242 
However, given the variation observed in incidence rates across age strata it is important that 243 
appropriate consideration be given to which is the most comparable age stratum to use. However, the 244 
specific age stratum of interest is often unlikely to be available in the literature. The interactive 245 
spreadsheet we provide in Supplementary File 3 should allow the reader to obtain incidence rates and 246 
expected numbers of events for the stratum that is most comparable to the one from which their 247 
observed events are derived; it also allows sensitivity analyses assuming a level of underestimation, 248 
whereby the reader can specify a percentage of seizures they assume the CPRD has missed when 249 
calculating expected numbers of events. Such a resource should prove useful in future studies 250 
reporting background incidence rates for use in post-marketing surveillance. 251 
Conclusions 252 
The results reported in this study provide reference or background incidence rates that can be used 253 
in the postmarketing surveillance of vaccines and other products with the potential to cause seizures. 254 
However, given the potential for underascertainment of seizure events, and the variation observed 255 
across age strata, care must be taken when interpreting and using these rates.  256 
 257 
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 384 
  Table 1. Age category specific rates of febrile seizure, afebrile seizure and generalised convulsive seizure (GCS). Includes all events 
occurring in the study population during follow up (i.e. multiple events per individual included) 
 
   
All events 
Age category (months)  GCS  Febrile  Afebrile 
  n IR CI95  n IR CI95  n IR CI95 
2-12  4768 8.34 (8.11-8.58)  3174 5.56 (5.37-5.75)  1595 2.79 (2.66-2.93) 
13-24  10341 16.63 (16.31-16.95)  8550 13.77 (13.48-14.07)  1793 2.88 (2.75-3.02) 
25-60  9933 6.13 (6.01-6.25)  6838 4.23 (4.13-4.33)  3097 1.91 (1.85-1.98) 
61-120  3290 1.95 (1.88-2.02)  966 0.58 (0.54-0.61)  2324 1.38 (1.32-1.43) 
121-180  585 1.41 (1.29-1.52)  94 0.23 (0.18-0.28)  491 1.18 (1.08-1.29) 
 385 
 386 
 387 
  Table 2. Age category specific rates of first febrile seizure, afebrile seizure and generalised convulsive seizure (GCS). Includes only the 
first event per individual during follow up (i.e. multiple events per individual not included). 
 
  First events only 
Age category (months)  GCS  Febrile  Afebrile 
   n IR CI95  n IR CI95  n IR CI95 
2-12  3659 6.42 (6.21-6.63)  2669 4.68 (4.50-4.86)  1105 1.93 (1.82-2.05) 
13-24  7232 11.76 (11.49-12.03)  6386 10.38 (10.13-10.63)  1145 1.85 (1.74-1.96) 
25-60  5502 3.46 (3.37-3.55)  4280 2.69 (2.61-2.67)  1689 1.05 (1.00-1.10) 
61-120  1637 0.99 (0.94-1.04)  609 0.37 (0.34-0.40)  1243 0.74 (0.70-0.78) 
121-180   306 0.75 (0.67-0.84)   71 0.17 (0.14-0.22)   265 0.64 (0.57-0.72) 
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Table 3 Proportion of febrile seizures identified using different case identification methods 
Identification method N cases % total 
Read code for Febrile Seizure 15,733 (80.1) 
Read code for seizure and Read code for fever or febrile seizure code within 7 days 600 (3.1) 
Read code for seizure and Read code for fever or febrile seizure code within 14 days 152 (0.8) 
Read code for seizure and free text containing a string related to fever*  within 7days 2,830 (14.4) 
Read code for seizure and free text containing a string related to fever*  within 14 days 307 (1.6) 
Febrile seizures 19622 (100) 
*Text strings related to fever include “*fever*”, “*febrile*”, “*pyrex*”, “*temp*” 
 396 
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Table 4. Comparison with the literature 
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Study Period children 
born in 
Country A&E a First/All 
events 
Study 
perspective 
Age  
(months old) 
Outcome b IR (per 
1000PY) 
Equivalent 
CPRD IRc 
  
Electronic health record studies 
VAESCO [16] 1993-<2009 UK No Alld Retrospective 0-59 GCS 7.4 9.0 
VAESCO [16] 1991-<2008 Netherlands No Alld Retrospective 0-59 GCS 7.8 9.0 
VAESCO [16] 1993-<2009 Spain No Alld Retrospective 0-59 GCS 5.0 9.0 
VAESCO [16] 1999-<2008 Finland No Alld Retrospective 0-59 GCS 8.9 9.0 
VAESCO [16] 1996-<2009 Italy No Alld Retrospective 0-59 GCS 9.1 9.0 
VAESCO [16] 1995-<2009 Norway No Alld Retrospective 0-59 GCS 6.6 9.0 
VAESCO [16] 1992-<2008 Sweden No Alld Retrospective 0-59 GCS 4.5 9.0 
VAESCO [16] 1991-<2009 Denmark Yes Alld Retrospective 0-59 GCS 14.4 9.0 
Sun et al [11] 2003-<2009 Denmark Yes First Retrospective 3-17 FS 17.2 7.3 
Rasmussen et al [25] 1980-<2010 Denmark Yes Firsti Retrospective 12-47 FS 5.9 6.1 
          
          
  
Follow up studies 
Van den Berg et al [20] 1960-<1968 USA Yes First Prospective 0-59 GCS 6.5 6.0 
       FS 4.6 4.9 
       AFS 1.8 1.4 
Vestergaard et al [6] 1990-<1992 Denmark Yesf First Retrospective 3-59 FS 4.9%g 2.2% 
Verity et al [4] 1970- <1971h UK Yesf First Retrospective 0-59 FS 2.3%g 2.2% 
Sillanpaa et al [23] 1986-<1987 Finland Yesf  All Prospective 0-59 FS 14 6.7 
Annegers et al [5] 1935-<1985 USA Yes First Retrospective 0-59 FS 2.0% g 2.2% 
Verburgh et al [24] 1982-<1988 Netherlands No First Prospective 2-59 FS 5.5 4.9 
a A&E = Accident and Emergency b GCS = Generalised convulsive seizures, FS = Febrile seizures, AFS = afebrile seizure c Rates observed for similar outcome/age band in 
current study, however where rates in literature included events occurring before 2 months of age the CPRD rate will not.  d in the VAESCO study recurrent events within 2 
weeks of a first event were excluded. f Data collected through parental interview therefore A&E events assumed to be included gIncidence rate not available for these 
studies, prevalence shown instead, and CPRD prevalence for comparison is calculated among subset of individuals with complete follow up from 2 months up to 5 years of 
age (n= 237,832, ~20% of total study population). h Verity et al included children born in a single week in April 1970.iOnly primary discharge diagnoses included. 
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Figure 1 Incidence of febrile, afebrile and generalised convulsive seizures by month of age. 404 
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Figure 2 Incidence of first febrile, afebrile and generalised convulsive seizures by month of age. 408 
 409 
